United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $506.59, for a total value of $4,812,605.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $164,359,579.37. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
United Therapeutics Stock Performance
NASDAQ UTHR opened at $518.27 on Wednesday. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The stock has a 50-day moving average of $534.53 and a 200 day moving average of $536.74. The company has a market capitalization of $22.23 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 1.69 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.41 EPS. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.
Analysts Set New Price Targets
UTHR has been the topic of a number of research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen restated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Weiss Ratings upgraded United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, August 13th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $646.00.
Check Out Our Latest Stock Report on UTHR
Hedge Funds Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Beacon Pointe Advisors LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter worth $1,294,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in United Therapeutics during the second quarter valued at $19,702,000. Palo Alto Investors LP purchased a new position in United Therapeutics during the second quarter valued at $33,911,514,000. Empowered Funds LLC bought a new stake in United Therapeutics during the second quarter valued at about $19,939,000. Finally, United Capital Financial Advisors LLC bought a new stake in United Therapeutics during the second quarter valued at about $289,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
